{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:51:25Z","timestamp":1791575485561,"version":"4.3.4"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Circulating tumor cells (CTCs) must survive immune attack in the bloodstream before they can contribute to distant metastasis. Their immune phenotype, including checkpoint ligands, antigen-presentation molecules, and immunomodulatory features, can be assessed through serial blood sampling and may provide information complementary to established immunotherapy biomarkers. This review organizes CTC immune evasion across intravasation, circulatory transit, and colonization, and examines CTC-associated immune interactions while distinguishing direct CTC observations from evidence derived from tumor tissue, cell culture, or animal models. We review technologies for immune phenotyping and the clinical evidence linking CTC immune features to immunotherapy outcomes across cancer types. Current studies support further investigation of longitudinal CTC monitoring, but heterogeneous assays, small or retrospective cohorts, and limited prospective validation prevent routine treatment selection based on these readouts. We also discuss experimental approaches to disrupting CTC immune protection during vascular transit and outline a four-stage pathway from discovery and analytical validation to clinical utility and implementation. CTC immune phenotyping remains a research strategy whose clinical value must be established beyond tissue biomarkers, ctDNA, and standard clinical assessment.<\/jats:p>","DOI":"10.1186\/s40364-026-01015-w","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:41:11Z","timestamp":1791528071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation"],"prefix":"10.1186","volume":"14","author":[{"given":"Pengfei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renya","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"6024","key":"1015_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559\u201364. https:\/\/doi.org\/10.1126\/science.1203543.","journal-title":"Science"},{"issue":"1","key":"1015_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","volume":"59","author":"C Alix-Panabi\u00e8res","year":"2013","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59(1):110\u201318. https:\/\/doi.org\/10.1373\/clinchem.2012.194258.","journal-title":"Clin Chem"},{"issue":"7586","key":"1015_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massagu\u00e9","year":"2016","unstructured":"Massagu\u00e9 J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298\u2013306. https:\/\/doi.org\/10.1038\/nature17038.","journal-title":"Nature"},{"issue":"8","key":"1015_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781\u201391. https:\/\/doi.org\/10.1056\/NEJMoa040766.","journal-title":"N Engl J Med"},{"issue":"19","key":"1015_CR5","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302\u201309.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"1015_CR6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"6230","key":"1015_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172.","journal-title":"Science"},{"issue":"6382","key":"1015_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u201355. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"1015_CR9","doi-asserted-by":"crossref","unstructured":"Gibney GT, Weiner LM, Olszanski AJ. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. The Lancet Oncol. 2016;17(12):e542\u201351.","DOI":"10.1016\/S1470-2045(16)30406-5"},{"issue":"3","key":"1015_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350. https:\/\/doi.org\/10.1038\/s41568-019-0116-x.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1015_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208\u201322.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1015_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1015_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"7","key":"1015_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Liquid biopsy and minimal residual disease-latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409\u201324. https:\/\/doi.org\/10.1038\/s41571-019-0187-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1015_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrc3820","volume":"14","author":"C Alix-Panabi\u00e8res","year":"2014","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623\u201331. https:\/\/doi.org\/10.1038\/nrc3820.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1015_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H, et al. Immune checkpoint HLA-E: CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41(2):272\u201387.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.001.","journal-title":"Cancer Cell"},{"issue":"1","key":"1015_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-024-00646-3","volume":"10","author":"X Liu","year":"2024","unstructured":"Liu X, Zuo F, Song J, et al. Immune checkpoints HLA-E: CD94-NKG2A and HLA-C: KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance. Cell Discov. 2024;10(1):16. https:\/\/doi.org\/10.1038\/s41421-024-00646-3.","journal-title":"Cell Discov"},{"issue":"4","key":"1015_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670\u201391. https:\/\/doi.org\/10.1016\/j.cell.2016.11.037.","journal-title":"Cell"},{"issue":"3","key":"1015_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccell.2017.07.001","volume":"32","author":"B Strilic","year":"2017","unstructured":"Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer Cell. 2017;32(3):282\u201393. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.001.","journal-title":"Cancer Cell"},{"issue":"6024","key":"1015_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"Science"},{"issue":"6","key":"1015_CR21","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.celrep.2014.08.029","volume":"8","author":"DT Ting","year":"2014","unstructured":"Ting DT, Wittner BS, Ligorio M, et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014;8(6):1905\u201318.","journal-title":"Cell Rep"},{"issue":"6254","key":"1015_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1126\/science.aab0917","volume":"349","author":"DT Miyamoto","year":"2015","unstructured":"Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349(6254):1351\u201356. https:\/\/doi.org\/10.1126\/science.aab0917.","journal-title":"Science"},{"issue":"3","key":"1015_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","volume":"14","author":"M Mohme","year":"2017","unstructured":"Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14(3):155\u201367. https:\/\/doi.org\/10.1038\/nrclinonc.2016.144.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1015_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19(10):553\u201367. https:\/\/doi.org\/10.1038\/s41568-019-0180-2.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1015_CR25","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabieres","year":"2021","unstructured":"Alix-Panabieres C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1311.","journal-title":"Cancer Discov"},{"issue":"1","key":"1015_CR26","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-021-24386-0","volume":"12","author":"YF Sun","year":"2021","unstructured":"Sun YF, Wu L, Liu SP, et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat Commun. 2021;12(1):4091. https:\/\/doi.org\/10.1038\/s41467-021-24386-0.","journal-title":"Nat Commun"},{"issue":"13","key":"1015_CR27","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1016\/j.cell.2023.05.028","volume":"186","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, He C, Wang M, et al. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell. 2023;186(13):2765\u201382.e28. https:\/\/doi.org\/10.1016\/j.cell.2023.05.028.","journal-title":"Cell"},{"issue":"1","key":"1015_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21\u201345. https:\/\/doi.org\/10.1016\/j.cell.2016.06.028.","journal-title":"Cell"},{"issue":"15","key":"1015_CR29","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre A, Rashidian M, Reinhardt F, et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77(15):3982\u201389. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3292.","journal-title":"Cancer Res"},{"issue":"1","key":"1015_CR30","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5(1):5241. https:\/\/doi.org\/10.1038\/ncomms6241.","journal-title":"Nat Commun"},{"issue":"7702","key":"1015_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","volume":"556","author":"I Pastushenko","year":"2018","unstructured":"Pastushenko I, Brisebarre A, Sifrim A, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556(7702):463\u201368. https:\/\/doi.org\/10.1038\/s41586-018-0040-3.","journal-title":"Nature"},{"key":"1015_CR32","doi-asserted-by":"publisher","unstructured":"Lo HC, Boardman DA, Bhatt RS, et al. N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor. J Immunother Cancer. 2022;10(11):e005061. https:\/\/doi.org\/10.1136\/jitc-2022-005061.","DOI":"10.1136\/jitc-2022-005061"},{"key":"1015_CR33","doi-asserted-by":"publisher","unstructured":"Zhang Y, Liu X, Zeng L, et al. Mesenchymal stromal cells increase the natural killer resistance of circulating tumor cells via intercellular signaling of cGAS-STING-IFN\u03b2-HLA. Adv Sci. 2024;11(30):e2400888. https:\/\/doi.org\/10.1002\/advs.202400888.","DOI":"10.1002\/advs.202400888"},{"issue":"2","key":"1015_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A L\u00f3pez-Soto","year":"2017","unstructured":"L\u00f3pez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135\u201354. https:\/\/doi.org\/10.1016\/j.ccell.2017.06.009.","journal-title":"Cancer Cell"},{"issue":"24","key":"1015_CR35","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-04-1110","volume":"10","author":"S Meng","year":"2004","unstructured":"Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10(24):8152\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1110.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1015_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800. https:\/\/doi.org\/10.1038\/nm730.","journal-title":"Nat Med"},{"issue":"9","key":"1015_CR37","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.molonc.2015.05.009","volume":"9","author":"M Mazel","year":"2015","unstructured":"Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9(9):1773\u201382.","journal-title":"Mol Oncol"},{"key":"1015_CR38","doi-asserted-by":"publisher","first-page":"175883401775012","DOI":"10.1177\/1758834017750121","volume":"10","author":"G Kallergi","year":"2018","unstructured":"Kallergi G, Vetsika EK, Aggouraki D, et al. Evaluation of PD-L1\/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol. 2018;10:1758834017750121. https:\/\/doi.org\/10.1177\/1758834017750121.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1015_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/annonc\/mdx636","volume":"29","author":"M Ili\u00e9","year":"2018","unstructured":"Ili\u00e9 M, Szafer-Glusman E, Hofman V, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol. 2018;29(1):193\u201399.","journal-title":"Ann Oncol"},{"issue":"6","key":"1015_CR40","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201.","journal-title":"Cell Rep"},{"issue":"6","key":"1015_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nbt.2576","volume":"31","author":"I Baccelli","year":"2013","unstructured":"Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31(6):539\u201344. https:\/\/doi.org\/10.1038\/nbt.2576.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"1015_CR42","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1158\/0008-5472.CAN-13-1885","volume":"74","author":"G Steinert","year":"2014","unstructured":"Steinert G, Sch\u00f6lch S, Niemietz T, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014;74(6):1694\u2013704.","journal-title":"Cancer Res"},{"issue":"7","key":"1015_CR43","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis C, Sober C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731\u201343.e13.","journal-title":"Cell"},{"issue":"2","key":"1015_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/HEP.0000000000000934","volume":"79","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang Y, Zhang W, et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatology. 2024;79(2):425\u201341. https:\/\/doi.org\/10.1097\/HEP.0000000000000934.","journal-title":"Hepatology"},{"issue":"1","key":"1015_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-021-00267-y","volume":"9","author":"A Strati","year":"2021","unstructured":"Strati A, Zavridou M, Kallergi G, et al. Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomark Res. 2021;9(1):14. https:\/\/doi.org\/10.1186\/s40364-021-00267-y.","journal-title":"Biomark Res"},{"issue":"1","key":"1015_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-024-01789-1","volume":"9","author":"W Li","year":"2024","unstructured":"Li W, Zhang X, Wu F, et al. Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis. Signal Transduct Target Ther. 2024;9(1):145. https:\/\/doi.org\/10.1038\/s41392-024-01789-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1015_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259\u201371.e11.","journal-title":"Cell"},{"issue":"4","key":"1015_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36(4):385\u2013401.e8.","journal-title":"Cancer Cell"},{"issue":"7","key":"1015_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","volume":"11","author":"HG Ljunggren","year":"1990","unstructured":"Ljunggren HG, K\u00e4rre K. In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237\u201344. https:\/\/doi.org\/10.1016\/0167-5699(90)90097-S.","journal-title":"Immunol Today"},{"issue":"12","key":"1015_CR50","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7(12):1420\u201335.","journal-title":"Cancer Discov"},{"issue":"6669","key":"1015_CR51","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DS, O\u2019callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature. 1998;391(6669):795\u201399.","journal-title":"Nature"},{"issue":"9","key":"1015_CR52","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nrc3789","volume":"14","author":"CL Buchheit","year":"2014","unstructured":"Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014;14(9):632\u201341. https:\/\/doi.org\/10.1038\/nrc3789.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1015_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W 3rd, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):227\u201338.","journal-title":"Cancer Res"},{"issue":"1","key":"1015_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-023-01753-7","volume":"22","author":"J Dai","year":"2023","unstructured":"Dai J, Bhargava R, Bhatt RS, et al. Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination. Mol Cancer. 2023;22(1):63. https:\/\/doi.org\/10.1186\/s12943-023-01753-7.","journal-title":"Mol Cancer"},{"issue":"4","key":"1015_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/2159-8290.CD-19-1500","volume":"11","author":"X Hong","year":"2021","unstructured":"Hong X, Roh W, Sullivan RJ, et al. The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. Cancer Discov. 2021;11(4):855\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1500.","journal-title":"Cancer Discov"},{"issue":"1","key":"1015_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13046-020-1533-0","volume":"39","author":"BS Sun","year":"2020","unstructured":"Sun BS, Yao YQ, Pei BX, et al. Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation. J Exp Clin Cancer Res. 2020;39(1):25. https:\/\/doi.org\/10.1186\/s13046-020-1533-0.","journal-title":"J Exp Clin Cancer Res"},{"key":"1015_CR57","doi-asserted-by":"publisher","unstructured":"Zhu J, Liu Y, Zhang H, et al. Shear stress drives the cleavage activation of protease-activated receptor 2 by PRSS3\/mesotrypsin to promote invasion and metastasis of circulating lung cancer cells. Adv Sci. 2023;10(26):e2301059. https:\/\/doi.org\/10.1002\/advs.202301059.","DOI":"10.1002\/advs.202301059"},{"issue":"5","key":"1015_CR58","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2011.09.009.","journal-title":"Cancer Cell"},{"issue":"2","key":"1015_CR59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123\u201334. https:\/\/doi.org\/10.1038\/nrc3004.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1015_CR60","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","volume":"72","author":"T Placke","year":"2012","unstructured":"Placke T, \u00d6rgel M, Schaller M, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440\u201348.","journal-title":"Cancer Res"},{"issue":"1","key":"1015_CR61","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","volume":"105","author":"JS Palumbo","year":"2005","unstructured":"Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178\u201385.","journal-title":"Blood"},{"issue":"9826","key":"1015_CR62","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591\u2013601.","journal-title":"Lancet"},{"issue":"7745","key":"1015_CR63","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","volume":"566","author":"BM Szczerba","year":"2019","unstructured":"Szczerba BM, Castro-Giner F, Vetter M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566(7745):553\u201357. https:\/\/doi.org\/10.1038\/s41586-019-0915-y.","journal-title":"Nature"},{"issue":"8","key":"1015_CR64","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1172\/JCI67484","volume":"123","author":"J Cools-Lartigue","year":"2013","unstructured":"Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446\u201358.","journal-title":"J Clin Invest"},{"issue":"14","key":"1015_CR65","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1158\/0008-5472.CAN-09-4442","volume":"72","author":"JD Spicer","year":"2012","unstructured":"Spicer JD, McDonald B, Cools-Lartigue JJ, et al. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2012;72(14):3919\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4442.","journal-title":"Cancer Res"},{"issue":"5","key":"1015_CR66","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"\u00c1 Teijeira","year":"2020","unstructured":"Teijeira \u00c1, Garasa S, Gato M, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5):856\u201371.e8.","journal-title":"Immunity"},{"key":"1015_CR67","doi-asserted-by":"publisher","unstructured":"Albrengues J, Shields MA, Ng D, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361(6409):eaao 4227. https:\/\/doi.org\/10.1126\/science.aao4227.","DOI":"10.1126\/science.aao4227"},{"issue":"13","key":"1015_CR68","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1158\/0008-5472.CAN-20-3222","volume":"82","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Hu J, Li W, et al. Platelet TLR4-ERK5 axis facilitates NET-mediated capturing of circulating tumor cells and distant metastasis after surgical stress. Cancer Res. 2022;82(13):2373\u201386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3222.","journal-title":"Cancer Res"},{"issue":"3","key":"1015_CR69","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/gutjnl-2024-334618","volume":"74","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Chen H, et al. Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasis. Gut. 2025;74(3):458\u201372. https:\/\/doi.org\/10.1136\/gutjnl-2024-334618.","journal-title":"Gut"},{"issue":"5","key":"1015_CR70","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110\u201322. https:\/\/doi.org\/10.1016\/j.cell.2014.07.013.","journal-title":"Cell"},{"issue":"8","key":"1015_CR71","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398. https:\/\/doi.org\/10.1038\/s41577-020-00490-y.","journal-title":"Nat Rev Immunol"},{"issue":"1\u20132","key":"1015_CR72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","volume":"176","author":"S Gkountela","year":"2019","unstructured":"Gkountela S, Castro-Giner F, Szczerba BM, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176(1\u20132):98\u2013112.e14.","journal-title":"Cell"},{"issue":"5","key":"1015_CR73","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, Zhang H, Matei IR, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302\u201317. https:\/\/doi.org\/10.1038\/nrc.2017.6.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1015_CR74","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611\u201322. https:\/\/doi.org\/10.1038\/nrc3793.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"1015_CR75","doi-asserted-by":"publisher","first-page":"108105","DOI":"10.1016\/j.celrep.2020.108105","volume":"32","author":"C Donato","year":"2020","unstructured":"Donato C, Kunz L, Castro-Giner F, et al. Hypoxia triggers the intravasation of clustered circulating tumor cells. Cell Rep. 2020;32(10):108105.","journal-title":"Cell Rep"},{"key":"1015_CR76","doi-asserted-by":"publisher","unstructured":"Yang Z, Chen Y, He J, et al. Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis. J Clin Invest. 2025;135(4):e193521. https:\/\/doi.org\/10.1172\/JCI193521.","DOI":"10.1172\/JCI193521"},{"key":"1015_CR77","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhang H, Wang J, et al. Unfolded protein response kinase PERK supports survival and metastasis of circulating tumor cell clusters via SAM synthesis and H3K4me3-dependent PDGFB signaling. Cancer Commun (Lond). 2025;45(3):e70072. https:\/\/doi.org\/10.1002\/cac2.70072.","DOI":"10.1002\/cac2.70072"},{"issue":"9","key":"1015_CR78","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/2159-8290.CD-22-0644","volume":"13","author":"C Rodrigues Almeida","year":"2023","unstructured":"Rodrigues Almeida C, Shrestha S, Engstrom HA, et al. Dynamic glycoprotein hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent circulating tumor cell clusters in breast cancer. Cancer Discov. 2023;13(9):2094\u2013113. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0644.","journal-title":"Cancer Discov"},{"issue":"7171","key":"1015_CR79","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903\u201307. https:\/\/doi.org\/10.1038\/nature06309.","journal-title":"Nature"},{"issue":"1","key":"1015_CR80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","volume":"165","author":"S Malladi","year":"2016","unstructured":"Malladi S, Macalinao DG, Jin X, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016;165(1):45\u201360. https:\/\/doi.org\/10.1016\/j.cell.2016.02.025.","journal-title":"Cell"},{"issue":"7595","key":"1015_CR81","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature16985","volume":"531","author":"MB Headley","year":"2016","unstructured":"Headley MB, Bins A, Nip A, et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature. 2016;531(7595):513\u201317. https:\/\/doi.org\/10.1038\/nature16985.","journal-title":"Nature"},{"issue":"5","key":"1015_CR82","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2016.07.032","volume":"166","author":"D Clever","year":"2016","unstructured":"Clever D, Roychoudhuri R, Constantinides MG, et al. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche. Cell. 2016;166(5):1117\u201331.e14. https:\/\/doi.org\/10.1016\/j.cell.2016.07.032.","journal-title":"Cell"},{"issue":"5","key":"1015_CR83","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jhep.2025.01.027","volume":"82","author":"L Xu","year":"2025","unstructured":"Xu L, Chen Y, Li H, et al. Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity. J Hepatol. 2025;82(5):855\u201369. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.027.","journal-title":"J Hepatol"},{"issue":"1","key":"1015_CR84","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. https:\/\/doi.org\/10.1080\/20013078.2018.1535750.","journal-title":"J Extracell Vesicles"},{"key":"1015_CR85","doi-asserted-by":"publisher","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau 6977. https:\/\/doi.org\/10.1126\/science.aau6977.","DOI":"10.1126\/science.aau6977"},{"issue":"7718","key":"1015_CR86","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382\u201386. https:\/\/doi.org\/10.1038\/s41586-018-0392-8.","journal-title":"Nature"},{"issue":"2","key":"1015_CR87","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity. Cell. 2019;177(2):414\u201327.e13.","journal-title":"Cell"},{"issue":"4","key":"1015_CR88","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","volume":"24","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2664.","journal-title":"Clin Cancer Res"},{"issue":"6908","key":"1015_CR89","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734\u201338. https:\/\/doi.org\/10.1038\/nature01112.","journal-title":"Nature"},{"issue":"1","key":"1015_CR90","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","volume":"10","author":"M Czystowska-Kuzmicz","year":"2019","unstructured":"Czystowska-Kuzmicz M, Sosnowska A, Nowis D, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):3000. https:\/\/doi.org\/10.1038\/s41467-019-10979-3.","journal-title":"Nat Commun"},{"issue":"4","key":"1015_CR91","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity. 2019;50(4):924\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.024.","journal-title":"Immunity"},{"issue":"10","key":"1015_CR92","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096\u2013103. https:\/\/doi.org\/10.1038\/nm1096-1096.","journal-title":"Nat Med"},{"issue":"7","key":"1015_CR93","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.20141836","volume":"212","author":"T Kitamura","year":"2015","unstructured":"Kitamura T, Qian BZ, Soong D, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. The J Exp Med. 2015;212(7):1043\u201359.","journal-title":"The J Exp Med"},{"issue":"10","key":"1015_CR94","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1158\/0008-5472.CAN-12-4601","volume":"73","author":"TA Mace","year":"2013","unstructured":"Mace TA, Ameen Z, Collins A, et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 2013;73(10):3007\u201318.","journal-title":"Cancer Res"},{"issue":"1","key":"1015_CR95","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei C, Yang C, Wang S, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18(1):64. https:\/\/doi.org\/10.1186\/s12943-019-0976-4.","journal-title":"Mol Cancer"},{"key":"1015_CR96","doi-asserted-by":"publisher","first-page":"5727815","DOI":"10.1155\/2017\/5727815","volume":"2017","author":"L Ye","year":"2017","unstructured":"Ye L, Zhang F, Li H, et al. Circulating tumor cells were associated with the number of T lymphocyte subsets and NK cells in peripheral blood in advanced non-small-cell lung cancer. Dis Markers. 2017;2017:5727815.","journal-title":"Dis Markers"},{"issue":"6","key":"1015_CR97","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ncb3169","volume":"17","author":"B Costa-Silva","year":"2015","unstructured":"Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816\u201326. https:\/\/doi.org\/10.1038\/ncb3169.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"1015_CR98","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.devcel.2019.04.011","volume":"49","author":"I Wortzel","year":"2019","unstructured":"Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-mediated metastasis: communication from a distance. Dev Cell. 2019;49(3):347\u201360. https:\/\/doi.org\/10.1016\/j.devcel.2019.04.011.","journal-title":"Dev Cell"},{"issue":"1","key":"1015_CR99","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1039\/C3LC50644D","volume":"14","author":"C Alix-Panabi\u00e8res","year":"2014","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Technologies for detection of circulating tumor cells: facts and vision. Lab Chip. 2014;14(1):57\u201362. https:\/\/doi.org\/10.1039\/C3LC50644D.","journal-title":"Lab Chip"},{"issue":"3","key":"1015_CR100","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf S, Fritsche H, M\u00fcller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13(3):920\u201328.","journal-title":"Clin Cancer Res"},{"key":"1015_CR101","doi-asserted-by":"publisher","unstructured":"Li H, Wang Y, Zhang J, et al. Digital quantitative detection for heterogeneous protein and mRNA expression patterns in circulating tumor cells. Adv Sci. 2025;12(2):e2410120. https:\/\/doi.org\/10.1002\/advs.202410120.","DOI":"10.1002\/advs.202410120"},{"issue":"1","key":"1015_CR102","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nnano.2016.239","volume":"12","author":"M Labib","year":"2017","unstructured":"Labib M, Green B, Mohamadi RM, et al. Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. Nat Nanotechnol. 2017;12(1):33\u201339. https:\/\/doi.org\/10.1038\/nnano.2016.239.","journal-title":"Nat Nanotechnol"},{"issue":"8","key":"1015_CR103","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/annonc\/mdx206","volume":"28","author":"A Strati","year":"2017","unstructured":"Strati A, Koutsodontis G, Papaxoinis G, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol. 2017;28(8):1923\u201333.","journal-title":"Ann Oncol"},{"issue":"6030","key":"1015_CR104","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.1198704","volume":"332","author":"SC Bendall","year":"2011","unstructured":"Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687\u201396. https:\/\/doi.org\/10.1126\/science.1198704.","journal-title":"Science"},{"issue":"7408","key":"1015_CR105","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nature11217","volume":"487","author":"M Yu","year":"2012","unstructured":"Yu M, Bardia A, Wittner BS, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487(7408):510\u201313. https:\/\/doi.org\/10.1038\/nature11217.","journal-title":"Nature"},{"issue":"8","key":"1015_CR106","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nm.3600","volume":"20","author":"CL Hodgkinson","year":"2014","unstructured":"Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20(8):897\u2013903. https:\/\/doi.org\/10.1038\/nm.3600.","journal-title":"Nat Med"},{"issue":"1","key":"1015_CR107","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-024-01984-2","volume":"23","author":"A Franken","year":"2024","unstructured":"Franken A, Honisch E, Engel F, et al. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells. Mol Cancer. 2024;23(1):112. https:\/\/doi.org\/10.1186\/s12943-024-01984-2.","journal-title":"Mol Cancer"},{"issue":"1","key":"1015_CR108","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41467-019-10122-2","volume":"10","author":"YH Cheng","year":"2019","unstructured":"Cheng YH, Chen YC, Lin E, et al. Hydro-seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat Commun. 2019;10(1):2163. https:\/\/doi.org\/10.1038\/s41467-019-10122-2.","journal-title":"Nat Commun"},{"issue":"7618","key":"1015_CR109","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature19328","volume":"537","author":"NV Jordan","year":"2016","unstructured":"Jordan NV, Bardia A, Wittner BS, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016;537(7618):102\u201306. https:\/\/doi.org\/10.1038\/nature19328.","journal-title":"Nature"},{"issue":"9","key":"1015_CR110","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nmeth.4380","volume":"14","author":"M Stoeckius","year":"2017","unstructured":"Stoeckius M, Hafemeister C, Stephenson W, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14(9):865\u201368. https:\/\/doi.org\/10.1038\/nmeth.4380.","journal-title":"Nat Methods"},{"issue":"7173","key":"1015_CR111","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/nature06385","volume":"450","author":"S Nagrath","year":"2007","unstructured":"Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235\u201339. https:\/\/doi.org\/10.1038\/nature06385.","journal-title":"Nature"},{"key":"1015_CR112","doi-asserted-by":"crossref","unstructured":"Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47.","DOI":"10.1126\/scitranslmed.3005616"},{"issue":"5","key":"1015_CR113","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/0008-5472.CAN-14-2613","volume":"75","author":"L Cayrefourcq","year":"2015","unstructured":"Cayrefourcq L, Mazard T, Joosse S, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015;75(5):892\u2013901.","journal-title":"Cancer Res"},{"issue":"6193","key":"1015_CR114","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.1253533","volume":"345","author":"M Yu","year":"2014","unstructured":"Yu M, Bardia A, Aceto N, et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216\u201320. https:\/\/doi.org\/10.1126\/science.1253533.","journal-title":"Science"},{"issue":"20","key":"1015_CR115","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","volume":"10","author":"WJ Allard","year":"2004","unstructured":"Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897\u2013904.","journal-title":"Clin Cancer Res"},{"issue":"41","key":"1015_CR116","doi-asserted-by":"publisher","first-page":"16580","DOI":"10.1073\/pnas.1313594110","volume":"110","author":"JC Fischer","year":"2013","unstructured":"Fischer JC, Niederacher D, Topp SA, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A. 2013;110(41):16580\u201385.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"1015_CR117","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"key":"1015_CR118","doi-asserted-by":"publisher","first-page":"31726","DOI":"10.1038\/srep31726","volume":"6","author":"C Nicolazzo","year":"2016","unstructured":"Nicolazzo C, Raimondi C, Mancini M, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab. Sci Rep. 2016;6:31726.","journal-title":"Sci Rep"},{"issue":"3","key":"1015_CR119","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-023-06972-6","volume":"200","author":"J Luo","year":"2023","unstructured":"Luo J, Chen Y, Wang H, et al. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy. Breast Cancer Res Treat. 2023;200(3):443\u201353. https:\/\/doi.org\/10.1007\/s10549-023-06972-6.","journal-title":"Breast Cancer Res Treat"},{"key":"1015_CR120","doi-asserted-by":"publisher","unstructured":"He Y, Liu H, Wang J, et al. PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy. J Immunother Cancer. 2025;13(3):e013381. https:\/\/doi.org\/10.1136\/jitc-2025-013381.","DOI":"10.1136\/jitc-2025-013381"},{"issue":"31","key":"1015_CR121","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.22.00219","volume":"40","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Pal SK, Hahn AW, et al. Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma. J Clin Oncol. 2022;40(31):3633\u201341. https:\/\/doi.org\/10.1200\/JCO.22.00219.","journal-title":"J Clin Oncol"},{"key":"1015_CR122","doi-asserted-by":"publisher","unstructured":"Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 2018;7(7):e1438111. https:\/\/doi.org\/10.1080\/2162402X.2018.1438111.","DOI":"10.1080\/2162402X.2018.1438111"},{"issue":"10","key":"1015_CR123","first-page":"1840","volume":"123","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Graf RP, Salber PE, et al. Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival. Cancer. 2017;123(10):1840\u201349.","journal-title":"Cancer"},{"issue":"5","key":"1015_CR124","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699\u2013713. https:\/\/doi.org\/10.1016\/j.cell.2010.07.044.","journal-title":"Cell"},{"issue":"12","key":"1015_CR125","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37(12):946\u201353.","journal-title":"J Clin Oncol"},{"key":"1015_CR126","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ebiom.2019.03.018","volume":"42","author":"S Lian","year":"2019","unstructured":"Lian S, Xie R, Ye Y, et al. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 2019;42:281\u201395. https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.018.","journal-title":"EBioMedicine"},{"issue":"17","key":"1015_CR127","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRP\u03b1) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662\u201367.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"1015_CR128","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018;379(18):1711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1807315.","journal-title":"N Engl J Med"},{"issue":"2","key":"1015_CR129","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du H, Hirabayashi K, Bhojnagarwala PS, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221\u201337.e8.","journal-title":"Cancer Cell"},{"key":"1015_CR130","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1038\/ncomms10582","volume":"7","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy. Nat Commun. 2016;7:10582.","journal-title":"Nat Commun"},{"key":"1015_CR131","doi-asserted-by":"crossref","unstructured":"Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450):eaar 3342.","DOI":"10.1126\/scitranslmed.aar3342"},{"issue":"2","key":"1015_CR132","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccell.2023.01.008","volume":"41","author":"L Ducimeti\u00e8re","year":"2023","unstructured":"Ducimeti\u00e8re L, Diep Luciani A, Pasqual N, et al. NKG2A blocks the anti-metastatic functions of natural killer cells. Cancer Cell. 2023;41(2):232\u201347.e6. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.008.","journal-title":"Cancer Cell"},{"issue":"5","key":"1015_CR133","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, Michelakos T, Kuber N, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27(5):1227\u201335.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1015_CR134","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540\u201355. https:\/\/doi.org\/10.1038\/nrc3982.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1015_CR135","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus C, Boligan KF, Chijioke O, et al. Interactions between siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014;124(4):1810\u201320.","journal-title":"J Clin Invest"},{"issue":"12","key":"1015_CR136","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1158\/0008-5472.CAN-14-0728","volume":"74","author":"C B\u00fcll","year":"2014","unstructured":"B\u00fcll C, Stoel MA, den Brok MH, Adema GJ. Sialic acids sweeten a tumor\u2019s life. Cancer Res. 2014;74(12):3199\u2013204.","journal-title":"Cancer Res"},{"issue":"3","key":"1015_CR137","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nri.2018.3","volume":"18","author":"E Rodr\u00edguez","year":"2018","unstructured":"Rodr\u00edguez E, Schetters STT, van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018;18(3):204\u201311. https:\/\/doi.org\/10.1038\/nri.2018.3.","journal-title":"Nat Rev Immunol"},{"key":"1015_CR138","doi-asserted-by":"crossref","unstructured":"Nicolazzo C, Raimondi C, Francescangeli F, et al. EpCAM-expressing circulating tumor cells in colorectal cancer. Int J Biol Markers. 2017;32(4):e415\u201320.","DOI":"10.5301\/ijbm.5000284"},{"issue":"1","key":"1015_CR139","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jagger B, Chen H, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136.","journal-title":"Nat Commun"},{"issue":"10","key":"1015_CR140","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209\u201315.","journal-title":"Nat Med"},{"key":"1015_CR141","doi-asserted-by":"publisher","unstructured":"Raimondi C, Carpino G, Nicolazzo C, et al. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system? Oncoimmunology. 2017;6(12):e1315488. https:\/\/doi.org\/10.1080\/2162402X.2017.1315488.","DOI":"10.1080\/2162402X.2017.1315488"},{"issue":"7","key":"1015_CR142","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/ijms21072653","volume":"21","author":"S Amintas","year":"2020","unstructured":"Amintas S, Bedel A, Moreau-Gaudry F, Boutin J, Buscail L, Merlio J-P, et al. Circulating tumor cell clusters: united we stand divided we fall. IJMS. 2020;21(7):2653. https:\/\/doi.org\/10.3390\/ijms21072653.","journal-title":"IJMS"},{"issue":"1","key":"1015_CR143","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13073-020-00728-3","volume":"12","author":"F Castro-Giner","year":"2020","unstructured":"Castro-Giner F, Aceto N. Tracking cancer progression: from circulating tumor cells to metastasis. Genome Med. 2020;12(1):31. https:\/\/doi.org\/10.1186\/s13073-020-00728-3.","journal-title":"Genome Med"},{"issue":"9","key":"1015_CR144","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0134-3.","journal-title":"Nat Med"},{"key":"1015_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2016.02.036","volume":"228","author":"J Li","year":"2016","unstructured":"Li J, Sharkey CC, Wun B, Liesveld JL, King MR. Genetic engineering of platelets to neutralize circulating tumor cells. J Control Release. 2016;228:38\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2016.02.036.","journal-title":"J Control Release"},{"issue":"2","key":"1015_CR146","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1021\/acsnano.1c09318","volume":"16","author":"H Li","year":"2022","unstructured":"Li H, Wang Y, Zhang J, et al. Localized degradation of neutrophil extracellular traps by photoregulated enzyme delivery for cancer immunotherapy and metastasis suppression. ACS Nano. 2022;16(2):2585\u201397. https:\/\/doi.org\/10.1021\/acsnano.1c09318.","journal-title":"ACS Nano"},{"issue":"1","key":"1015_CR147","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-024-03486-6","volume":"31","author":"S Gkountela","year":"2025","unstructured":"Gkountela S, Szczerba BM, Donato C, et al. Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nat Med. 2025;31(1):104\u201313. https:\/\/doi.org\/10.1038\/s41591-024-03486-6.","journal-title":"Nat Med"},{"issue":"6","key":"1015_CR148","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1910607.","journal-title":"N Engl J Med"},{"issue":"2","key":"1015_CR149","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Bhatti DL. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell STEM Cell. 2018;23(2):181\u201392.e5. https:\/\/doi.org\/10.1016\/j.stem.2018.06.002.","journal-title":"Cell STEM Cell"},{"issue":"9","key":"1015_CR150","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","journal-title":"Cancer Discov"},{"issue":"6","key":"1015_CR151","doi-asserted-by":"publisher","first-page":"165","DOI":"10.15698\/cst2019.06.188","volume":"3","author":"L Keller","year":"2019","unstructured":"Keller L, Werner S, Pantel K. Biology and clinical relevance of EpCAM. Cell Stress. 2019;3(6):165\u201380. https:\/\/doi.org\/10.15698\/cst2019.06.188.","journal-title":"Cell Stress"},{"issue":"9","key":"1015_CR152","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398\u2013406. https:\/\/doi.org\/10.1016\/j.molmed.2010.07.001.","journal-title":"Trends Mol Med"},{"issue":"4","key":"1015_CR153","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","volume":"15","author":"FC Bidard","year":"2014","unstructured":"Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet Oncol. 2014;15(4):406\u201314.","journal-title":"The Lancet Oncol"},{"issue":"2","key":"1015_CR154","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41551-018-0190-5","volume":"2","author":"M Poudineh","year":"2018","unstructured":"Poudineh M, Sargent EH, Pantel K, Kelley SO. Profiling circulating tumour cells and other biomarkers of invasive cancers. Nat Biomed Eng. 2018;2(2):72\u201384. https:\/\/doi.org\/10.1038\/s41551-018-0190-5.","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"1015_CR155","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/cyto.a.23576","volume":"93","author":"LL Zeune","year":"2018","unstructured":"Zeune LL, de Wit S, Berghuis AMS, et al. How to agree on a CTC: evaluating the consensus in circulating tumor cell scoring. Cytometry A. 2018;93(12):1202\u201306. https:\/\/doi.org\/10.1002\/cyto.a.23576.","journal-title":"Cytometry A"},{"key":"1015_CR156","doi-asserted-by":"publisher","first-page":"573165","DOI":"10.1155\/2015\/573165","volume":"2015","author":"CM Svensson","year":"2015","unstructured":"Svensson CM, Krusber R, Kamprad N, et al. Automated classification of circulating tumor cells and the impact of interobserver variability on classifier training and performance. J Immunol Res. 2015;2015:573165.","journal-title":"J Immunol Res"},{"issue":"10","key":"1015_CR157","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cyto.a.22993","volume":"89","author":"TB Lannin","year":"2016","unstructured":"Lannin TB, Thege FI, Kirby BJ. Comparison and optimization of machine learning methods for automated classification of circulating tumor cells. Cytometry A. 2016;89(10):922\u201331. https:\/\/doi.org\/10.1002\/cyto.a.22993.","journal-title":"Cytometry A"},{"key":"1015_CR158","doi-asserted-by":"crossref","unstructured":"Galanzha EI, Menyaev YA, Yadem AC, et al. In vivo liquid biopsy using cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma. Sci Transl Med. 2019;11(496):eaat 5857.","DOI":"10.1126\/scitranslmed.aat5857"},{"issue":"8","key":"1015_CR159","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/ijc.23717","volume":"123","author":"W He","year":"2008","unstructured":"He W, Kularatne SA, Kalli KR, et al. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer. 2008;123(8):1968\u201373.","journal-title":"Int J Cancer"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01015-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01015-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01015-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:03:41Z","timestamp":1791572621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-01015-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":159,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01015-w","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the content, and agree to publish.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are solely responsible for the conception, content and conclusions of this review. All scientific content, the interpretation of the cited literature, and the conclusions drawn are the authors\u2019 own. Figures\n                      \n                      \u2013\n                      \n                      were designed and drawn by the authors using Adobe Illustrator; no generative AI tool was used to create, modify or edit any image in this manuscript. For this revision the authors redrew all five figures in full and verified every graphical element, label and abbreviation, together with the corresponding legends, against the cited sources. Assistance from AI-based tools was limited to language editing and to improving the readability of the text; such tools were not used to generate, analyse or interpret data, and were not used to select, summarise or format the cited literature, which was verified by the authors against the primary sources.","order":3,"name":"Ethics","label":"AI contribution statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"139"}}